MedCity News November 18, 2024
Approval of Syndax’s Revuforj for acute leukemia makes the twice-daily pill the first in a new class of drugs that block a cancer-driving protein called menin. Other companies developing menin inhibitors include Kura Oncology, Biomea Fusion, and Johnson & Johnson subsidiary Janssen.
Syndax Pharmaceuticals has won FDA approval for a drug addressing advanced cases of acute leukemia carrying a particular genetic signature that leads to an aggressive form of the disease. The regulatory decision makes the Syndax drug the first therapy in a new class of medicines for blood cancers.
The FDA approval specifically covers the treatment of adults and children age 1 and older. The Syndax drug, a twice-daily pill known in development as revumenib, will be marketed under...
Today's Sponsors
Today's Sponsor